Vera Therapeutics (NASDAQ:VERA - Get Free Report) announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06), Zacks reports. During the same period in the previous year, the business posted ($0.56) EPS.
Vera Therapeutics Trading Down 0.6%
NASDAQ:VERA traded down $0.12 during mid-day trading on Thursday, reaching $21.07. 41,836 shares of the company's stock traded hands, compared to its average volume of 774,915. The company has a 50 day moving average price of $23.76 and a 200-day moving average price of $34.33. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -8.07 and a beta of 1.28. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.61.
Wall Street Analyst Weigh In
VERA has been the subject of several research reports. Guggenheim lifted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Cantor Fitzgerald lowered their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Wolfe Research initiated coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 target price on the stock. JPMorgan Chase & Co. lowered their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. Finally, HC Wainwright started coverage on Vera Therapeutics in a research note on Monday, May 5th. They set a "buy" rating and a $75.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Vera Therapeutics presently has an average rating of "Buy" and an average target price of $63.33.
Get Our Latest Stock Analysis on Vera Therapeutics
Vera Therapeutics Company Profile
(
Get Free Report)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Read More
Before you consider Vera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.
While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
